Overview

• Is differentiation possible or even necessary in the biosimilars market? Although the impetus for a biosimilar development originally might have been solely economic, we argue thatmmanufacturers should devise a value proposition for biosimilars that moves beyond price, demonstrating value to payers, physicians, and patients.
• Presenting a unifying value framework as a guiding tool for biosimilar manufacturers supporting internal processes - for example: Building internal business cases for differentiating concepts with the end goal to develop a value-enhancing strategy.